Lifecore Biomedical, Inc. - Common Stock LFCR 深 滬
交易中 10-31 10:55:58 美东时间
7.17
+0.070
+0.99%
華盛通- 最 高7.20
- 今 開7.09
- 成交量 1.13万股
- 最 低 6.97
- 昨 收 7.10
- 總市值 2.65亿
- 52周最高 8.85
- 市盈率 靜 --
- 換手率 0.03%
- 52周最低 4.76
- 委 比 -28.63%
- 總股本 3702.53万
- 歷史最高 15.96
- 量 比 0.34
- 振 幅 3.24%
- 歷史最低 1.52
- 每 手 1
- 風險率 0.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lifecore Expands CDMO Business, Becomes Supplier Of Choice For Leading Injectable Drug
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed an agreement with a leading global pharmaceutical
10-29 19:23
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
Lifecore Biomedical has signed two agreements: one to transfer commercial manufacturing of a leading injectable pharmaceutical product from a global pharmaceutical company, making it the new supplier, and another with an early-stage biotech company for pre-clinical formulation development. These signings highlight Lifecore's growing reputation and support its growth strategies, including expanding CDMO business and domestic manufacturing capacity...
10-29 11:00
LifeStance to Present at the UBS Global Healthcare Conference
LifeStance Health Group, a leading U.S. provider of outpatient mental health care, announced that CEO Dave Bourdon will present at the UBS Global Healthcare Conference on November 10, 2025, at 4:15 p.m. ET. The presentation, moderated by Kevin Caliendo, will be webcast live and available on the company’s Investor Relations website at investor.lifestance.com. A replay will also be accessible post-event. LifeStance, founded in 2017, operates across...
10-28 20:10
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
Lifecore Biomedical and PolyPeptide Laboratories have signed a collaboration agreement to offer integrated, end-to-end solutions for peptide-based pharmaceutical customers in the U.S. The partnership combines PolyPeptide's peptide manufacturing expertise with Lifecore's formulation, fill/finish, and packaging capabilities, aiming to accelerate development timelines, reduce costs, and ensure a reliable U.S.-based supply chain. The collaboration wi...
10-28 11:00
LifeStance to Host Third Quarter 2025 Earnings Conference Call on November 6, 2025
LifeStance Health Group will release its Q3 2025 earnings on November 6, 2025, before market open. A live earnings conference call will be held at 8:30 a.m. ET on the same day. Domestic participants may dial 1-800-715-9871, while international participants may dial 1-646-307-1963, using conference ID 3958273. A webcast will be available on the Events and Presentations section of the LifeStance Investor Relations website at https://investor.lifest...
10-16 20:10
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference
Minneapolis-based Lifecore Biomedical announced its participation in the 24th Annual Contract Pharma Conference in New Brunswick, NJ on Sept. 18-19 as a Gold Sponsor. The company will showcase its expertise in injectable pharmaceutical development and manufacturing at the event, aiming to enhance brand visibility and attract high-value business. Lifecore, a leading CDMO with over 40 years of experience, will also host customer meetings to expand ...
09-04 20:05
Keybanc Initiates Coverage On Lifecore Biomedical with Sector Weight Rating
Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector Weight rating.
09-04 17:44
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical announced its participation in three upcoming investor conferences: Morgan Stanley Global Healthcare Conference (Sept 8-10, New York), Barrington Research Virtual Fall Conference (Sept 16), and Jefferies CDMO Summit (Sept 17, London). Management will engage in fireside chats and investor meetings. A webcast of the Morgan Stanley session will be available on their investor website. Lifecore is an integrated CDMO specializing in...
09-02 20:05
Lifecore Biomedical Sees FY2026 Sales $74.000M-$76.000M vs $127.802M Est
Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $74.000 million-$76.000 million vs $127.802 million analyst estimate.
08-08 04:39
Lifecore Biomedical Q4 EPS $(0.06) Beats $(0.10) Estimate, Sales $36.444M Beat $35.363M Estimate
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 36.84 percent. This is a 70 percent increase over losses of $(0.20) per share from
08-08 04:14
